EFNA2

EFNA2 (Ephrin-A2/ELF-1) is a GPI-anchored, membrane-bound ligand for multiple Eph-family receptor tyrosine kinases that functions as a topographically graded guidance cue in the developing nervous system (PMID:7522971, PMID:7634327). It binds and activates the receptors Mek4, Sek, Cek7, Bsk, Cek8, and MDK1, triggering receptor autophosphorylation and downstream tyrosine phosphorylation, with high-affinity binding to MDK1 (Kd ~1.7 × 10⁻¹⁰ M) (PMID:7522971, PMID:7876076, PMID:8855326, PMID:9010230). Productive receptor activation requires membrane-bound or clustered presentation; unclustered soluble ligand is inactive (PMID:9232603). Functionally, EFNA2 acts as a repellent axon guidance factor with selective topographic activity—repelling temporal but not nasal retinal axons—and its expression in complementary gradients in the tectum and septum establishes positional labels that pattern retinotectal and hippocamposeptal projection maps; clustered EFNA2 also inhibits motoneuron neurite growth (PMID:7634327, PMID:8797822, PMID:9135142, PMID:8855326, PMID:9232603). Beyond neural development, EFNA2 is induced by stiff extracellular matrix and acts as a mechanotransduction effector promoting proliferation, migration, EMT, and tumor growth in hypopharyngeal cancer (PMID:40091591). Its downstream signaling effectors beyond receptor activation remain largely uncharacterized in the available corpus.

1. 1994 High

   Established the molecular identity of EFNA2 as a GPI-anchored membrane ligand for Eph-family receptors, answering what class of molecule it is and how it is displayed.

   Evidence Receptor-AP fusion binding (RAP in situ), cDNA cloning, and PI-PLC sensitivity in cell surface assays

   PMID:7522971

   Open questions at the time

   • Downstream signaling consequences of receptor binding not addressed
   • Physiological context of expression not yet defined
2. 1995 High

   Demonstrated that EFNA2 and its receptor Mek4 are expressed in reciprocal complementary gradients, providing the molecular basis for a positional-label system in topographic map formation.

   Evidence RNA in situ hybridization plus AP-fusion binding on retinotectal tissue sections

   PMID:7634327

   Open questions at the time

   • Correlational gradient mapping does not prove functional guidance
   • Mechanism of how graded binding translates to axon positioning unresolved
3. 1995 Medium

   Confirmed EFNA2 functionally activates a receptor (Cek7) by inducing autophosphorylation, establishing it as a bona fide receptor activator beyond mere binding.

   Evidence cDNA cloning, sequence analysis, and receptor autophosphorylation assay

   PMID:7876076

   Open questions at the time

   • Downstream effectors of Cek7 activation not identified
   • Single lab, limited orthogonal validation
4. 1996 High

   Provided direct in vitro and in vivo evidence that EFNA2 is a repellent guidance cue with nasal-temporal selectivity, settling whether the gradient is functionally instructive for retinotectal specificity.

   Evidence In vitro stripe/collapse assay and retroviral overexpression in vivo with axon mapping

   PMID:8797822

   Open questions at the time

   • Signaling pathway mediating repulsion not defined
   • Basis of nasal vs temporal differential response unexplained at this stage
5. 1996 High

   Extended EFNA2's guidance role beyond the retinotectal system, showing it patterns hippocamposeptal projections via the Bsk receptor through graded, topographically selective neurite control.

   Evidence In situ hybridization, neurite outgrowth assay, receptor binding, and tyrosine kinase activation assay

   PMID:8855326

   Open questions at the time

   • Intracellular signaling downstream of Bsk activation unresolved
   • How selectivity between medial and lateral neurons is encoded not determined
6. 1997 High

   Clarified the functional distinction between EFNA2 and related ephrins, linking its selective repellent activity to the strength of receptor interaction on RGC axons.

   Evidence Two independent in vitro assays (stripe and collapse) with receptor binding correlation

   PMID:9135142

   Open questions at the time

   • Molecular basis of differential receptor affinity not structurally defined
7. 1997 High

   Identified clustering/membrane presentation as a strict requirement for EFNA2 receptor activation, defining a key mechanistic constraint on its signaling, and extended its function to motoneuron axon growth.

   Evidence Receptor phosphorylation and neurite growth inhibition assays comparing clustered Fc-chimeric vs soluble forms

   PMID:9232603

   Open questions at the time

   • Stoichiometry and geometry of functional clusters not resolved
   • Downstream growth-inhibitory effectors unidentified
8. 1997 High

   Quantified high-affinity binding to the MDK1 receptor and detected a downstream phosphorylation event, advancing understanding of the proximal signaling output.

   Evidence Scatchard analysis, receptor autophosphorylation, phosphotyrosine western blotting, and PI-PLC treatment in Rat1 cells

   PMID:9010230

   Open questions at the time

   • Identity of the 62 kDa phosphoprotein never established
   • Functional consequence of MDK1 activation not characterized
9. 1998 Medium

   Defined the human EFNA2 genomic structure, showing conservation of the receptor-binding exon architecture across ephrin-A family members.

   Evidence Genomic cloning, intron/exon analysis, and sequence comparison

   PMID:9465306

   Open questions at the time

   • No functional inference beyond structural conservation
   • Single method, single lab
10. 2025 Medium

    Implicated EFNA2 as a mechanotransduction effector in cancer, showing matrix stiffness induces its expression to drive proliferation, migration, and EMT, a role outside its developmental guidance functions.

    Evidence Hydrogel stiffness model, EFNA2 gene editing, colony/EDU/Transwell assays, EMT marker blotting, and xenografts in hypopharyngeal cancer cells

    PMID:40091591

    Open questions at the time

    • Upstream pathway linking stiffness sensing to EFNA2 induction not resolved
    • Whether Eph-receptor signaling mediates the pro-tumorigenic effect not tested
    • Single lab
11. 2023 Low

    Positioned EFNA2 as a downstream node of a circRNA-miRNA axis regulating osteogenic differentiation, implicating it in Wnt-dependent BMSC biology.

    Evidence RIP assay, luciferase reporter, overexpression/knockdown, and OVX mouse model

    PMID:36764273

    Open questions at the time

    • EFNA2 role established only indirectly as a downstream target; not independently validated as a protein effector
    • Direct molecular link between EFNA2 and Wnt inactivation not demonstrated

• The intracellular signaling effectors transducing EFNA2-driven Eph receptor activation and how its developmental guidance role connects to its cancer mechanotransduction function remain unresolved.
• No defined downstream signaling cascade beyond receptor autophosphorylation
• 62 kDa phosphoprotein and other effectors unidentified
• No structural model of ligand-receptor selectivity